Tocilizumab is associated with reduced delirium and coma in critically ill patients with COVID-19

Abstract Recent preclinical studies demonstrate a direct pathological role for the interleukin-6 (IL-6) pathway in mediating structural and functional delirium-like phenotypes in animal models of acute lung injury. Tocilizumab, an IL-6 pathway inhibitor, has shown reduced duration of ventilator depe...

詳細記述

書誌詳細

出版年:	Scientific Reports
主要な著者:	Tuqa Alkhateeb, Joanna L. Stollings, Ine Sohn, Dandan Liu, L. Montana Fleenor, E. Wesley Ely, Shouri Lahiri
フォーマット:	論文
言語:	英語
出版事項:	Nature Portfolio 2024-05-01
主題:	Tocilizumab Delirium COVID-19 Sars-CoV-2 ICU Interleukin-6
オンライン･アクセス:	https://doi.org/10.1038/s41598-024-62505-1